Loading...
Charles River Laboratories International, Inc.
CRL•NYSE
Healthcare
Medical - Diagnostics & Research
$176.93
$-0.17(-0.10%)
Charles River Laboratories International, Inc. (CRL) Financial Performance & Income Statement Overview
Review Charles River Laboratories International, Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
-1.92%
↓ 1.92%
Operating Income Growth
-63.17%
↓ 63.17%
Net Income Growth
-95.32%
↓ 95.32%
Operating Cash Flow Growth
7.41%
↑ 7.41%
Operating Margin
4.38%
↑ 4.38%
Gross Margin
32.43%
↑ 32.43%
Net Profit Margin
-0.78%
↓ 0.78%
ROE
-0.89%
↓ 0.89%
ROIC
2.70%
↑ 2.70%
Charles River Laboratories International, Inc. (CRL) Income Statement & Financial Overview
Review Charles River Laboratories International, Inc.'s (CRL) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $1.003B | $1.010B | $1.03B | $1.01B |
| Cost of Revenue | $718.30M | $660.74M | $690.65M | $691.37M |
| Gross Profit | $284.24M | $349.02M | $335.46M | $320.19M |
| Gross Profit Ratio | $0.28 | $0.35 | $0.33 | $0.32 |
| R&D Expenses | $0.00 | $0.00 | $0.00 | $0.00 |
| SG&A Expenses | $195.71M | $199.21M | $165.85M | $177.22M |
| Operating Expenses | $451.93M | $199.21M | $165.85M | $177.22M |
| Total Costs & Expenses | $1.17B | $859.96M | $856.51M | $868.58M |
| Interest Income | $1.83M | $1.53M | $3.01M | $2.20M |
| Interest Expense | $28.23M | $30.28M | $32.77M | $35.001M |
| Depreciation & Amortization | $102.10M | $88.20M | $86.08M | $85.36M |
| EBITDA | -$86.45M | $209.72M | $238.50M | $219.37M |
| EBITDA Ratio | -$0.09 | $0.21 | $0.23 | $0.22 |
| Operating Income | -$167.69M | $117.41M | $169.61M | $142.98M |
| Operating Income Ratio | -$0.17 | $0.12 | $0.17 | $0.14 |
| Other Income/Expenses (Net) | -$49.10M | -$26.16M | -$32.00M | -$43.97M |
| Income Before Tax | -$216.79M | $91.24M | $119.65M | $99.01M |
| Income Before Tax Ratio | -$0.22 | $0.09 | $0.12 | $0.10 |
| Income Tax Expense | -$3.04M | $20.95M | $25.39M | $24.53M |
| Net Income | -$213.41M | $68.68M | $89.99M | $67.33M |
| Net Income Ratio | -$0.21 | $0.07 | $0.09 | $0.07 |
| EPS | -$4.22 | $1.34 | $1.75 | $1.42 |
| Diluted EPS | -$4.22 | $1.33 | $1.74 | $1.41 |
| Weighted Avg Shares Outstanding | $51.14M | $51.39M | $51.55M | $51.44M |
| Weighted Avg Shares Outstanding (Diluted) | $51.14M | $51.58M | $51.85M | $51.84M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan